Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1α/VEGF signaling pathway

Fig. 2

Relationship between the expressions of TET3 and AHR mRNA and the prognosis of THCA patients. A.H. The expressions of TET3 and AHR in tumor tissue were significantly higher than in normal tissue in the THCA data set. B.I. The TET3 and AHR expression levels were significantly lower in the tumor grade 1 subgroup than in the tumor grade 2/3 subgroup and lower in the tumor grade 2 subgroup than in the tumor grade 3 subgroup. C.J The expressions of TET3 and AHR were higher in Caucasian, African-Americans and Asians. D.K. The expressions of TET3 and AHR were higher in women. E.L. The expressions of TET3 and AHR were higher in patients aged 21–60 years. F.M. The expressions of TET3 and AHR were classical and tall THCA. G.N. Patients with lymph node metastasis demonstrated a higher expression of TET3 and AHR.

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us